Loading...
•
Dec 31, 2019
Bio-Rad Q4 2019 Earnings Report
Bio-Rad reported an increase in net sales and a significant rise in net income, influenced by a favorable change in the fair market value of equity securities.
Key Takeaways
Bio-Rad Laboratories reported Q4 2019 net sales of $624.4 million, a 1.2% increase year-over-year. Net income for the quarter was $553.5 million, or $18.31 per share, compared to a net loss in Q4 2018. The company experienced a cyberattack during the quarter that impacted sales and operations.
Q4 net sales increased by 1.2% to $624.4 million, or 2.3% on a currency-neutral basis.
Life Science segment sales increased by 1.0% to $242.0 million.
Clinical Diagnostics segment sales increased by 1.6% to $379.0 million.
Net income was $553.5 million, or $18.31 per share, significantly impacted by changes in the fair market value of equity securities.
Bio-Rad
Bio-Rad
Bio-Rad Revenue by Segment
Revenue by Segment
Life Science Revenue
CapyFin.comClinical Diagnostics Revenue
CapyFin.com Forward Guidance
For the full year 2020, Bio-Rad anticipates currency-neutral revenue growth of approximately 4.5 to 5.25 percent and improved profitability with an estimated non-GAAP operating margin of 13.8 to 14.3 percent.
Positive Outlook
- Expect another year of progress.
- Driven by a combination of healthy markets.
- Driven by new products.
- Focus on operating efficiencies.
- Continue to pursue goal of 20 percent adjusted EBITDA run rate by the end of the year.
Challenges Ahead
- Future gains and charges are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance.
- Foreign currency fluctuations.
- Future gains or losses associated with certain legal matters.
- Acquisitions.
- Restructuring activities.
Revenue & Expenses
Visualization of income flow from segment revenue to net income